KORU Medical Systems, Inc. (KRMD)
- Previous Close
2.7200 - Open
2.9500 - Bid 3.2800 x 100
- Ask 3.8400 x 200
- Day's Range
2.9500 - 3.3350 - 52 Week Range
1.8600 - 5.0500 - Volume
250,789 - Avg. Volume
160,721 - Market Cap (intraday)
152.496M - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1300 - Earnings Date May 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.50
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 and FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
www.korumedical.comRecent News: KRMD
View MorePerformance Overview: KRMD
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRMD
View MoreValuation Measures
Market Cap
125.50M
Enterprise Value
119.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.70
Price/Book (mrq)
7.46
Enterprise Value/Revenue
3.56
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.03%
Return on Assets (ttm)
-14.47%
Return on Equity (ttm)
-32.64%
Revenue (ttm)
33.65M
Net Income Avi to Common (ttm)
-6.07M
Diluted EPS (ttm)
-0.1300
Balance Sheet and Cash Flow
Total Cash (mrq)
9.58M
Total Debt/Equity (mrq)
23.73%
Levered Free Cash Flow (ttm)
116.92k